Target intelligence / Profile preview

MicroRNA 320c-1 (miR-320c-1)

Target
miR-320c-1
Molecular classification
microRNA, Non-coding RNA, Regulatory RNA, Other
01

Overview

MicroRNA 320c-1 (miR-320c-1) is a small non-coding RNA molecule of the microRNA family that post-transcriptionally regulates gene expression by binding to target mRNAs, leading to mRNA degradation or translational inhibition[5]. miR-320c-1 is encoded in the human genome and functions as a regulatory molecule in diverse biological processes, including DNA damage response, cell proliferation, and apoptosis. It has been implicated in various diseases such as cancer (promoting or reducing chemoresistance by regulating genes like CHK1 and SMARCC1), osteoarthritis (serving as a plasma biomarker and affecting cytokine expression), and pulmonary disease (modulating SERPINA1 and inflammation). Due to these activities, miR-320c-1 is explored as a therapeutic target and biomarker for patient selection and monitoring in several clinical contexts[1][2][3][4][5].

Other names
hsa-mir-320c-1MIR320C-1MIRN320C1mir-320c-1MIR320C1
02

Mechanism of action

Modulates drug responsiveness by regulating target gene expression (e.g., suppresses DNA damage checkpoint kinase Chk1, regulates chromatin remodeling via SMARCC1, suppresses CREB5, regulates SERPINA1). miR-320c mimics or inhibitors can sensitize or desensitize tumor cells to chemotherapeutic agents by altering expression of key target genes

03

Biological functions

Negative regulation of gene expression (post-transcriptional)Modulation of DNA damage responseRegulation of cellular proliferationApoptosis modulationRegulation of inflammatory signaling
04

Disease associations

Cancer (including breast and pancreatic cancer)OsteoarthritisInflammationPulmonary disease (implicated in alpha-1 antitrypsin deficiency)
05

Safety considerations

Potential for off-target effects when modulating miRNA levels systemically, as miRNAs commonly regulate multiple genes/pathwaysRisk of impacting multiple physiological processes due to broad regulatory roles in cell proliferation, apoptosis, and inflammation
06

Interacting drugs

Oxaliplatin

1 more in the full profile.

07

Biomarkers

Plasma miR-320c can serve as a biomarker for diagnosis and severity assessment in osteoarthritisMarker for oxaliplatin responsiveness in triple-negative breast cancer

Beyond the preview

Go deeper on MicroRNA 320c-1 (miR-320c-1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroRNA 320c-1 (miR-320c-1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call